 This research study is conducted in patients with previously untreated, high-risk Diffuse Large B-cell Lymphoma DLBCL. Patients with high-risk DLBCL typically have insufficient therapeutic outcomes. Therefore, the addition of novel agents to the currently used induction therapy R-CHOP backbone is a rational approach to improve therapeutic outcomes in this disease setting. 